Email Page Print Page

Technology Platform

New advances in drug delivery technologies are allowing many existing products to be administered with improved effectiveness, speed, safety and/or ease of administration. Drug delivery technologies are also facilitating the advancement of many new drugs which might not otherwise be feasible without an effective means of administration.

BioDelivery Sciences utilizes patented and proprietary drug delivery technologies to create products and formulations that meet important patient and healthcare provider needs. Presently, our development efforts are centered on the BioErodible MucoAdhesive (BEMA®) technology.

 

BEMA TechnologyBEMA Technology

The BEMA® drug delivery technology consists of a small, bioerodible polymer film for application to the mucosal membranes (inner lining of cheek). BEMA® films were designed to rapidly deliver a dose of drug across the mucous membranes for time sensitive conditions or to facilitate administration of drugs with poor oral (pill) absorption.

BEMA® films are designed to:

 

  • Adhere to oral mucosa in less than 5 seconds
  • Optimize delivery across the oral mucosa
  • Completely dissolve within 15 to 30 minutes


The first product to be developed and marketed using the BEMA® technology was Onsolis® (fentanyl buccal soluble film). Following the successful development and approval of the first product utilizing the BEMA® technology, we began to apply the same technology to improve the delivery of other therapies, such as buprenorphine and buprenorphine/naloxone. The BEMA® technology may also be developed with other active drugs, particularly in conditions where rapid delivery of drug is important, oral dosing is not optimal, or where intravenous line or injections are unavailable or not practical. BDSI owns the worldwide rights to the BEMA® drug delivery technology.

 

 

Learn More

TECHNOLOGY PLATFORM MENU

Get the latest details on our products and services.

Top News

BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development
Previously announced interim data showed pain improvement compared to placebo; results not replicated in patients enrolled post interim analysis


BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Year-End 2014 Financial Results
2014 - A Year of Many Significant Milestones, with More Expected for 2015, as BDSI Continues its Growth as an Integrated Specialty Pharmaceutical Company